Clinical trial
Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants…
NCT00098163 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00098163 |
|---|---|
| Title | Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers |
| Official title | A Phase I Study to Evaluate the Safety and Immunogenicity of ALVAC-HIV vCP1521 in Infants Born to HIV-1 Infected Women in Uganda |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) NIH National Institute on Drug Abuse (NIDA) National Institute of Mental Health (NIMH) |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | ALVAC-HIV vCP1521, ALVAC HIV-1 vCP1521 |
| Enrollment | 60 |
| Completion | May 1, 2009 |
| First posted | Dec 6, 2004 |
| Last update posted | Nov 1, 2021 |
| Countries | Uganda |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: